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Abstract: Background: Cholesterol efflux is an important mechanism by which high-density lipopro-
teins (HDLs) protect against cardiovascular disease. As peripheral artery disease (PAD) is associated
with high mortality rates, mainly due to cardiovascular causes, we investigated whether cholesterol
efflux capacity (CEC) of apolipoprotein B (apoB)-depleted plasma, a widely used surrogate of HDL
function, may serve as a predictive marker for mortality in this patient population. Methods: In this
prospective single-center study (median follow-up time: 9.3 years), apoB-containing lipoproteins
were precipitated from plasma of 95 patients with PAD and incubated with J744-macrophages, which
were loaded with radiolabeled cholesterol. CEC was defined as the fractional radiolabel released
during 4 h of incubation. Results: Baseline CEC was lower in PAD patients that currently smoked
(p = 0.015) and had a history of myocardial infarction (p = 0.011). Moreover, CEC showed a significant
correlation with HDL-cholesterol (p = 0.003) and apolipoprotein A-I levels (p = 0.001) as well as
the ankle-brachial index (ABI, p = 0.018). However, CEC did not differ between survivors and non-
survivors. Neither revealed Kaplan–Meier and Cox regression analyses any significant association of
CEC with all-cause mortality rates. Conclusion: Taken together, CEC is associated with ABI but does
not predict all-cause mortality in patients with PAD.
Keywords: cholesterol efflux capacity; high-density lipoprotein; peripheral artery disease; risk pre-
diction
1. Introduction
Peripheral artery disease (PAD) is a very prevalent condition in developed countries.
Around one in five people over the age of 65 suffer from PAD [1] and the number of PAD
patients is expected to increase facing the growing elderly population. Individuals with
PAD are at high risk for morbidity and mortality, especially caused by cardiovascular
events like myocardial infarction, stroke, and critical limb ischemia [2]. According to data
from the Reduction of Atherothrombosis for Continued Health (REACH) registry patients
with PAD exhibited a cardiovascular event rate (composite of myocardial infarction, stroke,
vascular death, and rehospitalization due to vascular events) of 21% after one year of
follow-up and increasing to 40% at 3 years [3]. Notably, the probability of patients with
PAD experiencing a future cardiovascular event was even higher as patients with coronary
artery disease or cerebrovascular disease [3]. Accurate and early identification of PAD
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patients at high risk of future cardiovascular morbidity and mortality is therefore essential.
However, the high comorbidity rates and the many therapeutic interventions among this
group of patients make outcome prediction with conventional risk factors, such as smoking,
diabetes, hypertension, and hyperlipidemia, challenging. Consequently, alternative or
additional markers are required to improve risk stratification.
The ability of high-density lipoprotein (HDL) particles to remove cholesterol from
lipid-laden macrophages, the first step in reverse cholesterol transport, is a crucial mecha-
nism by which HDLs protect against atherosclerotic cardiovascular disease (CVD) [4,5].
Recent findings highlight the importance of HDL functionality measurements, particularly
in cholesterol efflux capacity (CEC), over measurement of HDL-cholesterol (HDL-C) levels
for cardiovascular risk assessment. Studies based on samples from the general population
found that CEC is inversely associated with future cardiovascular events, independent of
HDL-C concentration and other traditional cardiovascular risk factors [6–9]. Likewise, the
ability of apolipoprotein B (apoB)-depleted serum to accept cholesterol from macrophages
was a predictor of mortality in patients with established coronary artery disease [10–13]. It
has not yet been investigated whether macrophage-specific CEC is linked to outcome in
patients with PAD. Therefore, the aim of this study was to assess whether HDL CEC could
predict mortality in PAD patients and to explore which factors impact CEC in this specific
patient population.
2. Materials and Methods
This single-center prospective cohort study included 95 patients with PAD (73 male
and 22 female) with or without a history of peripheral vascular intervention or vas-
cular surgery. PAD was confirmed either angiographically, sonographically, and/or
with ankle-brachial index (ABI)-measurement. Patients were recruited between 2002
and 2005 and were followed up until 2016. The mean age at enrollment was 68.3 years
(range 47.3–86.3 years). A primary visit was performed at which written informed consent
was obtained from all patients after proper explanation of the study and its purpose to
the patients. In the case where patients were willing to participate, they were invited for
a second study visit. All subjects could withdraw from the study at any time. The study
protocol was approved by the Cantonal Ethics Committee of Zurich and is in line with the
principles of the Declaration of Helsinki.
Non-Laboratory Measurements and Definitions: Information concerning the medical
history, current medication, previous cardiovascular and cerebrovascular events, hyper-
tension, dyslipidemia, and diabetes mellitus were obtained from all subjects at the initial
screening visit by interviewing the patient and reviewing the electronic hospital chart.
Diabetes was defined as fasting serum glucose ≥7 mmol/L or use of oral antidiabetics or
insulin. Hyperlipidemia was defined as use of lipid-lowering drugs or total cholesterol
>5.2 mmol/L and/or triglycerides >2.26 mmol/L. Hypertension was defined as a systolic
blood pressure ≥140 mm Hg and/or a diastolic blood pressure ≥90 mm Hg. Smoking
was defined as active cigarette smoking. The body mass index was calculated as weight
in kilograms divided by height in meters squared. The ABI and carotid intima-media
thickness (cIMT) were measured in all participants at the time of the second visit. The ABI
was determined with the patient in supine position after 20 min of rest using the Vicorder
system (Skidmore Medical Ltd., Bristol, UK). The systolic pressure was obtained in both
arms and at the tibial anterior as well as tibial posterior artery in each ankle. The ABI
was calculated by dividing the highest ankle pressure by the highest systolic pressure
of the arm. The cIMT was assessed using a high-resolution ultrasound transducer and
semiautomatic edge-detection software (GE Healthcare, Glattbrugg, Switzerland). The
cIMT of the dorsal wall of both common carotid arteries, proximal to the carotid bulb, was
measured according to international recommendations [14].
The Fontaine-stage classification was used to grade the severity of the clinical symp-
toms: stage I asymptomatic, stage IIa claudication at distance >200 m, and stage IIb
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claudication at distance <200 m. Three patients had a complicated PAD with minor ulcer
but no resting pain (stage IIc).
Laboratory Measurements: All laboratory measurements were performed using the
baseline lithium-heparin plasma samples available from the second visit between 2002
and 2004. Total cholesterol was measured using the cholesterol oxidase-4 aminophenazone
(CHOD-PAP) method, HDL-cholesterol using the cholesterol esterase/cholesterol oxidase/4-
aminoantipyrine method, triglycerides using the glycerine phosphate oxidase-4
-aminophenazone (GPO-PAP) method, C-reactive protein (CRP) using an immunotur-
bimetric assay, and creatinine using a modified version of the Jaffé method, respectively,
all on a cobas 8000 modular analyzer (Roche Diagnostics, Rotkreuz, Switzerland). LDL-
cholesterol was calculated with the Friedewald formula [15]. Non-HDL-cholesterol was
derived by subtracting HDL-cholesterol from total cholesterol. The chronic kidney disease
epidemiology collaboration (CKD-EPI, 2009) equation was used to estimate the glomeru-
lar filtration rate [16]. Plasma apolipoprotein B (apoB) and apoA-I were determined by
immunonephelometric assays on a BN Prospec System (Siemens Healthcare Diagnostics,
Erlangen, Germany). Lipoprotein(a) (Lp(a)) was measured with an immunoturbidimetric
assay (Randox, Crumlin, UK) on a Konelab 30 clinical chemistry analyzer (Thermo Fisher
Diagnostics, Pratteln, Switzerland). Serum homocysteine was determined using a chemilu-
minescence microparticle assay on an Architect i2000SR immunoassay analyzer (Abbott,
Baar, Switzerland).
Assessment of Cholesterol Efflux Capacity: To obtain the apoB-free fraction, apoB-
containing lipoproteins were precipitated from K-EDTA plasma obtained at the initial
visit and biobanked at −80 ◦C until analysis using a mix of 8.2% tungstophosphoric acid
hydrate (Merck, Darmstadt, Germany) and 6.2% 1 M MgCl2 (Roth, Karlsruhe, Germany).
CEC was quantitated as reported previously [13,17,18]. The murine macrophage cell line
J774.1A (ATCC, Rockville, MD, USA) was cultured in Dulbecco’s Modified Eagle Medium
(Sigma-Aldrich, St. Louis, MO, USA) supplemented with 1% fetal bovine serum at 37 ◦C
in a humidified incubator (5% CO2, 95% air). For efflux experiments, cells were seeded in
96-well plates (50,000 cells per well). The J744 macrophages were then loaded overnight
with 2.5 µCi/mL 3H-cholesterol followed by equilibration in serum-free growth medium
containing 0.2% serum albumin. To induce ATP-binding cassette transporter A1 (ABCA1)
expression J774 cells were stimulated with 0.3 mM N6,2′-0-dibutyryladenosine 3′,5′-cyclic
monophosphate (cAMP, Sigma Aldrich, St. Louis, MO, USA). Thereafter, efflux medium
containing 2.8% apoB-depleted plasma was added to the macrophages for 4 h. All steps
were performed in the presence of 5 µg/mL acyl-coenzyme A cholesterol acyltransferase
inhibitor (Santa Cruz Biotechnology, Santa Cruz, CA, USA).
The effluxed cholesterol label was quantified by liquid scintillation counting. Values
obtained from control cells without added apoB-depleted plasma were subtracted to correct
for passive diffusion. Efflux per well was calculated according the following formula:
[(counts released into the medium containing 2.8% apoB-free plasma—counts released
into the medium without acceptor)/counts recovered from the cells extracted before the
efflux experiment] × 100. Values were normalized to values obtained with a pooled plasma
control run with each plate to correct for interassay variation across plates. Each sample
was run in triplicate.
Statistical Analyses: Statistical analyses were performed using IBM SPSS Statistics
version 26.0 (IBM Corp, Armonk, NY, USA) and GraphPad Prism version 8.0.0 (Graph-
Pad Software Inc., San Diego, CA, USA). Normally distributed continuous variables are
presented as mean ± standard deviation, whereas continuous variables with a skewed
distribution are summarized as medians with 25th and 75th percentiles. Categorical vari-
ables are given as numbers (percentages). Patient characteristics were analyzed separately
for gender-stratified tertiles of CEC. Differences between groups were tested for statistical
significance with one-way analysis of variance with subsequent Bonferroni post-hoc testing
for multiple comparisons for normally distributed continuous variables, with the Kruskal–
Wallis test for variables with a skewed distribution, and the chi-square test for categorical
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variables. Gender-adjusted linear regression analysis was carried out to determine the
contribution of variables to CEC. Log-transformation was used for variables with a skewed
distribution. Kaplan–Meier survival curves were plotted to evaluate the association of
CEC with mortality. The log-rank test was used to assess statistical differences among the
survival curves of the different cholesterol efflux tertiles. Univariate and multivariate Cox
proportional hazard regression analyses were employed to test the influence of CEC on
mortality. The results are reported as hazard ratios (HRs) per 1-standard deviation increase
with corresponding 95% confidence intervals (95% CIs). Statistical significance was defined
as p < 0.05.
3. Results
3.1. Patient Characteristics
In this single-center prospective cohort study, 95 PAD patients were enrolled between
2002 and 2004. At follow-up, in 2016, 50 of these patients were alive, 31 of these patients
were dead, and 13 patients were lost to follow-up. Patients that died during follow-up
were older and had a higher prevalence of diabetes mellitus. The sample volume was
insufficient for the cholesterol efflux measurement in one patient. Therefore, 81 patients
were included in the final data analysis. Participants were divided into gender-stratified
tertiles according to CEC. The median cholesterol efflux value was 85.0 (interquartile range
(IQR) 79.0–88.5) in the first tertile, 99.0 (IQR 95.5–102.0) in the second tertile, and 118.0
(IQR 111.0–135.0) in the third tertile (Table 1). PAD patients in the lowest tertile of CEC
had significantly lower HDL-C- and apoA-I-levels as compared to PAD patients in the
highest tertile of CEC (1.16 ± 0.36 mmol/L vs. 1.42 ± 0.41 mmol/L for HDL-C, p = 0.030,
and 1.36 ± 0.24 g/L vs. 1.56 ± 0.28 g/L for apoA-I, p = 0.009, Table 1). Moreover, these
patients had lower ABI values (0.76 ± 0.17 vs. 0.89 ± 0.18, p = 0.039, Table 1). Patients in
the lowest tertile had significantly more often a history of previous myocardial infarction
(MI) compared to patients in the mid and highest tertile (44% vs. 19%, p = 0.017, and 44%
vs. 15%, p = 0.040, Table 1). cIMT did not differ between tertiles of CEC (Table 1).
3.2. Determinants of CEC in PAD Patients
We next sought to define factors that influence CEC in patients with PAD. In all study
participants, CEC tended to be lower in males than in females (98.5 (87.0–110.0) vs. 105.0
(96.0–119.0), p = 0.051, Supplemental Figure S1a). Additionally, CEC was significantly lower
in current smokers than in non-smokers (95.0 (85.0–108.0) vs. 102.5 (94.0–117.5), p = 0.015,
Supplemental Figure S1b) and in patients with a history of MI than in patients without a
history of MI (89.0 (85.0–101.0) vs. 102.0 (92.5–117.0), p = 0.011, Supplemental Figure S1c).
However, there was no significant difference in CEC between PAD patients with or with-
out a history of a cerebrovascular accident (CVA, p = 0.132, Supplemental Figure S1d),
with or without diabetes (p = 0.722, Supplemental Figure S1e), with or without dyslipi-
demia (p = 0.721, Supplemental Figure S1f), or with or without hypertension (p = 0.817,
Supplemental Figure S1g). Because of the gender differences in CEC, gender-adjusted
regression analysis was used to determine the relationships of CEC with clinical and bio-
chemical variables. In agreement with the analyses of patient characteristics categorized by
tertiles of cholesterol efflux, CEC in PAD patients showed a strong correlation with plasma
HDL-C (β = 0.333, p = 0.003, Table 2) and apoA-I levels (β = 0.363, p = 0.001, Table 2).
Moreover, CEC correlated positively with ABI (β = 0.258, p = 0.018, Table 2) and this
association remained significant after further adjustment for HDL-C (β = 0.247, p = 0.017)
or apoA-I levels (β = 0.204, p = 0.049). On the other hand, CEC was not related to age, BMI,
other lipid parameters, plasma CRP, eGFR, and cIMT (Table 2).
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Table 1. Patient characteristics by gender-stratified tertiles of CEC.










Male gender, n (%) 22 (82) 21 (78) 21 (79) 0.928
Age, years 68.3 ± 8.9 68.5 ± 11.5 66.2 ± 8.9 0.648
Smoking, n (%) 19 (70) 12 (44) 14 (52) 0.142
History of MI, n (%) 12 (44) 5 (19) a 4 (15) b 0.026
History of CVA, n (%) 15 (56) 12 (44) 11 (41) 0.525
Diabetes, n (%) 10 (37) 5 (19) 7 (26) 0.306
Dyslipidemia, n (%) 21 (78) 18 (67) 23 (85) 0.271










Cholesterol, mmol/L 4.2 ± 1.1 4.5 ± 1.1 4.6 ± 0.9 0.317
HDL-cholesterol, mmol/L 1.16 ± 0.36 1.25 ± 0.34 1.42 ± 0.41 b 0.033
LDL-cholesterol, mmol/L 2.5 ± 1.8 2.7 ± 0.6 3.0 ± 0.8 0.665









ApoA-I, g/L 1.36 ± 0.24 1.48 ± 0.21 1.56 ± 0.28 b 0.012
ApoB, g/L 0.94 ± 0.17 0.90 ± 0.22 0.92 ± 0.19 0.688










CRP, mg/L 4.1 (2.2–6.3) 3.1 (1.6–6.4) 2.8 (1.3–4.8) 0.424
Kidney Function
eGFR, ml/min/1.73 m2 67 ± 20 70 ± 20 63 ± 21 0.410
Extent of PAD
ABI 0.76 ± 0.17 0.80 ± 0.23 0.89 ± 0.18 b 0.042
cIMT, mm 0.78 ± 0.13 0.77 ± 0.16 0.76 ± 0.11 0.792
Fontaine stage
0.596
Stage I 11 (41) 10 (37) 11 (41)
Stage IIa 7 (26) 11 (41) 12 (44)
Stage IIb 8 (30) 4 (15) 4 (15)
Stage IIc 1 (4) 2 (7) 0 (0)
Stage III 0 (0) 0 (0) 0 (0)
Stage IV 0 (0) 0 (0) 0 (0)
Data are expressed as mean ± standard deviation, median [interquartile range] or total (percentage). Differences between the groups were
tested with one-way analysis of variance followed by Bonferroni post hoc test for normally distributed variables, Kruskal–Wallis test for
variables with a skewed distribution, and chi-square test for categorical variables. a p < 0.05 first vs. second tertile, b p < 0.05 first vs. third
tertile. Abbreviations: MI, myocardial infarction; CVA, cerebrovascular accident; BMI, body mass index; HDL, high-density lipoprotein;
LDL, low-density lipoprotein; apoA-I, apolipoprotein A-I; apoB, apolipoprotein B; Lp(a), lipoprotein(a); CRP, C-reactive protein; eGFR,
estimated glomerular filtration rate; PAD, peripheral artery disease; ABI, ankle brachial index; IMT, intima-media thickness.
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Table 2. Relationship of traditional cardiovascular risk factors with CEC in patients with peripheral
artery disease.





















Gender-adjusted standardized regression coefficients (β) are shown. Not normally distributed parameter were
log transformed. Abbreviations: MI, myocardial infarction; CVA, cerebrovascular accident; BMI, body mass index;
HDL, high-density lipoprotein; LDL, low-density lipoprotein; apoA-I, apolipoprotein A-I; apoB, apolipoprotein B;
Lp(a), lipoprotein(a); CRP, C-reactive protein; eGFR, estimated glomerular filtration rate; PAD, peripheral artery
disease; ABI, ankle brachial index; IMT, intima-media thickness.
3.3. Association of Cholesterol Efflux with All-Cause Mortality
Median follow-up time was 9.3 years (range 0.4–14.7 years). At the end of the follow-
up period, 10 patients (37%) died in the first tertile of CEC, 9 patients (33%) in the second
tertile, and 12 patients in the third tertile (44%, p = 0.732, Figure 1). Similarly, Kaplan–
Meier survival curves revealed no difference in all-cause mortality rates over time among
the different tertiles of CEC (Figure 2, p = 0.812). As shown in Table 3, the unadjusted
HR (95% CI) for all-cause mortality per 1-SD increase in CEC was 0.843 (0.587–1.208)
(p = 0.352). Adding gender to the model did not significantly change the calculated HR
(0.867 (0.599–1.255), p = 0.449, Table 3). CEC remained unrelated to all-cause mortality after
adjustment for other potential confounders (Table 3). Of note, also none of the classic lipid
parameters, i.e., cholesterol, LDL-C, HDL-C, non-HDL-C, triglycerides, apoA-I, apoB, and
Lp(a), predicted mortality in our cohort of patients with PAD (Supplemental Table S1–S8).
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Figure 1. Mortality according to gender-stratified tertiles of CEC.
Figure 2. Kaplan–Meier curves for mortality by gender-stratified tertiles of CEC. Statistical difference
was determined using the log-rank test.
Table 3. Hazard ratios for mortality by CEC.
HR Per 1-SD Increment [95%CI] p-Value
Crude 0.843 (0.587–1.208) 0.352
Corrected for gender 0.867 (0.599–1.255) 0.449
Corrected for age and gender 0.925 (0.639–1.340) 0.680
Corrected for age, gender, and HDL-C 0.953 (0.651–1.398) 0.807
Corrected for age, gender, and ABI 0.932 (0.625–1.389) 0.729
Corrected for age, gender, and smoking 0.992 (0.675–1.457) 0.967
Data are expressed as hazard ratios (HR) per 1 standard deviation (SD) increment and their respective 95%
confidence intervals (CIs).
4. Discussion
PAD is associated with an elevated risk of cardiovascular events and shortened life
expectancy [19]. PAD patients regularly have polyvascular disease and exhibit a cardio-
vascular event rate of 40% within three years after first diagnosis [1]. Since conventional
risk factors inadequately identify PAD patients at high risk of poor prognosis, better risk
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prediction tools based on novel biomarkers are urgently needed. The development of
targeted therapies may help reduce cardiovascular events and hence, premature mortality
in PAD patients. In this study, we investigated the predictive value of CEC, an important
antiatherosclerotic functionality of HDLs, for mortality in PAD and determining factors
influencing HDL cholesterol efflux potential in this patient population.
Currently, recommendations for therapies in PAD patients are based on a risk as-
sessment that measures the severity of PAD with traditional markers such as ABI. Other
indicators such as the cIMT are under discussion. While patients with a low ABI (<0.4) have
a high risk for cardiovascular events and mortality, it is more uncertain in patients suffering
from an intermediately impaired arterial perfusion of the lower legs (ABI between 0.4–0.9).
We previously found that traditional markers of peripheral atherosclerosis, ABI and cIMT,
did not predict mortality in the PAD patient population used in this study [20]. This is
in concordance with other recent studies that questioned the predictive value of cIMT
in PAD patients [21,22]. There are new promising biomarkers, like the cardiac markers
heart-type fatty acid binding protein, highly sensitive troponin T, and N-terminal pro
b-type natriuretic peptide, and the inflammatory marker C-reactive protein, that have
received considerable attention for the prognosis of PAD patients in recent years [20,23–25].
However, these biomarkers are not yet used in clinical routine for cardiovascular risk
assessment in PAD patients.
A reduced HDL functionality, particularly in CEC, is increasingly recognized as an im-
portant cardiovascular risk factor. The efflux of excessive cholesterol from arterial macrophage
foam cells towards HDLs is the first step in the reverse cholesterol transport pathway, facili-
tating the removal of cholesterol from the body and key in the protection of HDLs against
atherosclerotic cardiovascular disease [4,5]. Previous studies reported that a lower CEC is
associated with an increased incidence of cardiovascular events and mortality in the general
population as well as patients with established coronary artery disease [6–8,10–13]. Further-
more, two comprehensive meta-analyses indicated that individuals with a higher CEC
have a reduced risk for major adverse cardiovascular events and all-cause mortality [9,26].
Contrary to these observations, we did not find any association between CEC and all-cause
mortality in PAD patients in the current study, even after adjustment for other potential
confounders. Notably, an inverse association between CEC and adverse outcome is not
present in all published studies. Our findings agree with a recent study indicating that
CEC had no predictive value for all-cause and cardiovascular mortality in renal transplant
recipients, another patient group with high cardiovascular mortality rates and failure of
traditional risk factors to adequately predict events [27]. Cahill et al. [28] measured CEC in
a nested case-control study of the Health Professionals Follow-up Study (HPFS) and found
no independent relationship between CEC and coronary heart disease events. Furthermore,
in a cohort of 1150 patients with suspected stable coronary artery disease undergoing
elective angiography, an increased CEC was paradoxically associated with a higher risk for
incident major adverse cardiovascular events, myocardial infarction, and stroke during
a follow-up of 3 years [29]. It is important to note that the comparability of published
clinical studies is limited due to the different assay protocols used to measure CEC and
these methodological differences may contribute to these discrepant results.
We have examined for the first time in a prospective cohort study the association of
CEC with mortality in PAD patients. Previous research in 1255 participants of the Multi-
Ethnic Study of Atherosclerosis reported that cholesterol efflux to apoB-depleted serum did
not differ between patients with or without PAD [30]. The same authors showed that CEC
was not associated with the development of clinical PAD and could not predict a future
decline in ABI [30]. Another study suggested that the relationship between CEC and PAD
is influenced by diabetes status since an impairment in CEC in the presence of PAD was
only observed in patients without diabetes or newly diagnosed diabetes but not in patients
with established diabetes [31]. Recently, investigators have examined the effects of exercise
training in PAD patients and showed that neither 24 weeks of supervised treadmill exercise
nor lower extremity resistance training improved HDL CEC in individuals with PAD [32].
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Another important finding that emerged from the present study is that CEC correlated
with ABI and this relationship remained robust after correction for HDL-C and apoA-I
levels. ABI is not only a marker of lower limb PAD but may also reflect the degree of
systemic atherosclerosis. These data are consistent with the concept that cholesterol efflux
from macrophages decreases foam cell formation and slows atherosclerosis development.
Therefore, a reduced potential to remove excess cholesterol from macrophage foam cells
may lead to a higher coronary and peripheral atherosclerotic burden in PAD patients.
Interestingly, the lack of a significant association between CEC and cIMT, another surrogate
indicator of subclinical atherosclerosis, does not support this hypothesis. A possible
explanation for this might be that the cIMT increases continuously with age and is linked
to other cardiovascular risk factors, like BMI, blood pressure, total cholesterol, triglycerides,
glucose, and smoking [33]. Additionally, it has been suggested that carotid plaque burden
is a better predictor of cardiovascular risk than cIMT [21,22,34].
Although our current study focused on CEC, it is essential to compare our obser-
vations with the impact of classic lipid markers on cardiovascular risk in PAD patients.
Dyslipidemia is a risk factor for both the manifestation and progression of PAD [35]. The
2017 European Society of Cardiology guidelines on the treatment of peripheral artery dis-
ease were updated in 2020 and state that an LDL-C target of <1.4 (1.8) mmol/L or at least a
50% decrease in baseline LDL-C should be achieved in all PAD patients [19,36]. Substantial
evidence from randomized clinical trials shows that statin therapy in patients with PAD
reduces the risk of major adverse cardiovascular events by approximately 20% [37,38].
Among the conventional lipid risk factors, the ratio of total to HDL-C emerged as the
strongest determinant of large vessel PAD in both the Physician’s Health Study and the
San Diego Population Study [39–41]. Low levels of HDL-C may predispose to adverse
outcomes as a perspective study including 254 patients suffering from PAD concluded
that patients with reduced HDL-C levels (<1.0 mmol/L for men and <1.3 mmol/L for
women) presented with higher incidences of mortality and major cardiovascular events
over a 3-year period [42]. In our study population, none of the traditional lipid parameters
was a useful biomarker for the early prediction of mortality in PAD patients.
Our study as several potential limitations. First, the generalizability is limited by the
relatively small sample size and the analyses of single-center data. We cannot exclude that
our sample size was too small to identify CEC as an independent predictor of all-cause
mortality in PAD patients and our results may not be transferable to a multicenter setting.
Another issue with the study design is that we investigated all-cause mortality and not
mortality due to major cardiovascular events. However, we were not able to perform
analyses specifically for cardiovascular mortality, as no data on the cause of death were
available in the current study. Additional to these considerations, the studied group of PAD
patients suffered from an intermediately impaired arterial perfusion and did not include
patients with severer forms of PAD, which are at very high risk for cardiovascular events
and death. Although our work provides important insights into the role of CEC in risk
prediction in PAD patients, the current findings need to be confirmed in a larger multicenter
setting. Future studies should also include patients with severe PAD (ABI < 0.4) as well as
patients with non-compressible arteries (ABI > 1.4) and the analyses should be extended to
major cardiovascular events and cardiovascular mortality.
5. Conclusions
In summary, the present study has demonstrated that CEC was associated with ABI
but not with mortality in patients with intermediate PAD. As long as there is uncertainty
about the value of biomarkers for predicting cardiovascular mortality in PAD patients, a
combination of biomarkers should be considered when stratifying the individual risk of
cardiovascular events.
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